An Open-label, Uncontrolled, Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Nivolumab/vorhyaluronidase alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 03 Jul 2025 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2024 New trial record